A Phase II Study of Azacitidine (Vidaza) Combined to Epoetin Beta (NeoRecormon) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA.

Trial Profile

A Phase II Study of Azacitidine (Vidaza) Combined to Epoetin Beta (NeoRecormon) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Azacitidine (Primary) ; Epoetin beta (Primary)
  • Indications Myelodysplastic syndromes; Refractory anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Mar 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 24 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top